ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypesRenata Vieira de Sá, R. Jeroen Pasterkamp, Emma Sudrià-Lopez et al.|Nature Communications|2024Cited by 31
Pharmacological validation of TDO as a target for Parkinson’s diseasePaula Perez‐Pardo, Aletta D. Kraneveld, Antoon M. van Doornmalen et al.|FEBS Journal|2021Cited by 29
Prebiotic diet normalizes aberrant immune and behavioral phenotypes in a mouse model of autism spectrum disorderNaika Prince, Paula Perez‐Pardo, Lucía N. Peralta Marzal et al.|Acta Pharmacologica Sinica|2024Cited by 24
Mouse strain-specific responses along the gut-brain axis upon fecal microbiota transplantation from children with autismNaika Prince, Paula Perez‐Pardo, Lucía N. Peralta Marzal et al.|Gut Microbes|2025Cited by 14